Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
CCL parancs
CCL
Összesen 3 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM120113
Első szerző:
Naveen, R.
Cím:
Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus : results from the COVAD study / Naveen R., Nikiphorou Elena, Joshi Mrudula, Sen Parikshit, Lindblom Julius, Agarwal Vishwesh, Lilleker James B., Tan Ai Lyn, Salim Babur, Ziade Nelly, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Kuwana Masataka, Day Jessica, Makol Ashima, Distler Oliver, Chinoy Hector, Traboco Lisa S., Wibowo Suryo Anggoro Kusumo, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, García-De La Torre Ignacio, COVAD Study Group, Aggarwal Rohit, Gupta Latika, Agarwal Vikas, Parodis Ioannis
Dátum:
2023
ISSN:
1462-0324 1462-0332
Megjegyzések:
Objective: To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). Methods: Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March-December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. Results: Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). Conclusion: While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
adverse events
rheumatology
systemic lupus erythematosus
vaccine
Megjelenés:
Rheumatology. - 62 : 7 (2023), p. 2453-2463. -
További szerzők:
Nikiphorou, Elena (reumatológus)
Joshi, Mrudula
Sen, Parikshit
Lindblom, Julius
Agarwal, Vishwesh
Lilleker, James B.
Tan, Ai Lyn
Salim, Babur
Ziade, Nelly
Velikova, Tsvetelina
Gracia-Ramos, Abraham Edgar
Kuwana, Masataka
Day, Jessica
Makol, Ashima
Distler, Oliver
Chinoy, Hector
Traboco, Lisa S.
Wibowo, Suryo Anggoro Kusumo
Tehozol, Erick Adrian Zamora
Serrano, Jorge Rojas
García-De La Torre, Ignacio
Aggarwal, Rohit
Gupta, Latika
Agarwal, Vikas
Parodis, Ioannis
Nagy-Vincze Melinda (1985-) (orvos)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
2.
001-es BibID:
BIBFORM110887
035-os BibID:
(WoS)000999243100001 (Scopus)85180733005
Első szerző:
Naveen, R.
Cím:
Flares in IIMs and the timeline following COVID-19 vaccination : a combined analysis of the COVAD-1 and 2 surveys / Naveen R., Sen Parikshit, Griger Zoltán, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Serrano Jorge Rojas, García-De La Torre Ignacio, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, Kibbi El Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., COVAD study group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:
2024
ISSN:
1462-0324 1462-0332
Megjegyzések:
Objectives: Disease flares in the post COVID-19 vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods: The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022 respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history, and vaccination details.Flares of IIMs were defined as a. patient self-reported, b. immunosuppression (IS) denoted, c. clinical sign directed, and d. with >7.9-point MCID worsening of PROMISPF10a score. Risk factors of flares were analyzed using regression models. Results: Of 15165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians), and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7%, and 19.6% patients by definitions a-d respectively with a median time to flare of 71.5 (10.7-235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR:1.2; 95%CI:1.03-1.6, p = 0.025) were prone to flares, while those receiving Rituximab (OR:0.3; 95%CI:0.1-0.7, p = 0.010) and Azathioprine (OR:0.3, 95%CI:0.1-0.8, p = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in immunosuppression. Asthma (OR: 1.62; 95%CI: 1.05-2.50, p = 0.028) and higher pain VAS (OR: 1.19; 95%CI: 1.11-1.27, p < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion: A diagnosis of IIMs confers an equal risk of flares in the post COVID-19 vaccination period to AIRDs, with active disease, female gender, and comorbidities conferring a higher risk. Disparity between patient and physician reported outcomes represents a future avenue for exploration.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 Vaccines
Disease Exacerbation
Idiopathic Inflammatory Myopathies
Patient Reported Outcomes
Megjelenés:
Rheumatology. - 63 : 1 (2024), p. 127-139. -
További szerzők:
Sen, Parikshit
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Day, Jessica
Joshi, Mrudula
Nune, Arvind
Nikiphorou, Elena (reumatológus)
Saha, Sreoshy
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Velikova, Tsvetelina
Milchert, Marcin
Jagtap, Kshitij
Parodis, Ioannis
Gracia-Ramos, Abraham Edgar
Cavagna, Lorenzo
Kuwana, Masataka
Knitza, Johannes
Chen, Yi Ming
Makol, Ashima
Agarwal, Vishwesh
Patel, Aarat
Pauling, John D.
Wincup, Chris
Barman, Bhupen
Zamora Tehozol, Erick Adrian
Serrano, Jorge Rojas
García-De La Torre, Ignacio
Colunga-Pedraza, Iris J.
Merayo-Chalico, Javier
Chibuzo, Okwara Celestine
Katchamart, Wanruchada
Akawatcharangura Goo, Phonpen
Shumnalieva, Russka
Hoff, Leonardo Santos
El Kibbi, Lina
Halabi, Hussein
Vaidya, Binit
Shaharir, Syahrul Sazliyana
Hasan, A. T. M. Tanveer
Dey, Dzifa
Gutiérrez, Carlos-Enrique Toro
Caballero-Uribe, Carlo Vinicio
Lilleker, James B.
Salim, Babur
Gheita, Tamer A.
Chatterjee, Tulika
Distler, Oliver
Saavedra, Miguel A.
Chinoy, Hector
Agarwal, Vikas
Aggarwal, Rohit
Gupta, Latika
Nagy-Vincze Melinda (1985-) (orvos)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
3.
001-es BibID:
BIBFORM109287
Első szerző:
Sen, Parikshit
Cím:
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis : a comparative analysis of the COVAD surveys / Parikshit Sen, Naveen R., Nazanin Houshmand, Siamak Moghadam Kia, Mrudula Joshi, Sreoshy Saha, Kshitij Jagtap, Vishwesh Agarwal, Arvind Nune, Elena Nikiphorou, Ai Lyn Tan, Samuel Katsuyuki Shinjo, Nelly Ziade, Tsvetelina Velikova, Marcin Milchert, Ioannis Parodis, Abraham Edgar Gracia-Ramos, Lorenzo Cavagna, Masataka Kuwana, Johannes Knitza, Ashima Makol, Aarat Patel, John D. Pauling, Chris Wincup, Bhupen Barman, Erick Adrian Zamora Tehozol, Jorge Rojas Serrano, Ignacio Garcia-De La Torre, Iris J. Colunga-Pedraza, Javier Merayo-Chalico, Okwara Celestine Chibuzo, Wanruchada Katchamart, Phonpen Akawatcharangura Goo, Russka Shumnalieva, Yi-Ming Chen, Leonardo Santos Hoff, Lina El Kibbi, Hussein Halabi, Binit Vaidya, Syahrul Sazliyana Shaharir, A. T. M. Tanveer Hasan, Dzifa Dey, Carlos Enrique Toro Gutièrrez, Carlo Vinicio Caballero-Uribe, James B. Lilleker, Babur Salim, Tamer Gheita, Tulika Chatterjee, Oliver Distler, Miguel A. Saavedra, Jessica Day, Hector Chinoy, COVAD Study Group
Dátum:
2023
ISSN:
1462-0324 1462-0332
Megjegyzések:
Objective: COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs), however hesitancy continues to persist among these patients.Therefore, we studied the prevalence, predictors, and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods: The 1st and 2nd COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analyzed using regression models in different groups. Results: We analyzed data from 18,882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) [OR 0.26; 95%CI: 0.24-0.30, p < 0.001]. However, concerns/fear over long-term safety had increased [OR 3.6;95% CI:2.9-4.6, p < 0.01].We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs [OR:1.8; 95%CI: 1.08-3.2, p = 0.023] and HCs [OR: 4; 95%CI: 1.9-8.1, p < 0.001], as well as more long-term safety concerns/fear [IIMs vs AIRDs; OR: 1.9; 95%CI: 1.2-2.9, p = 0.001; IIMs vs HCs; OR: 5.4 95%CI: 3-9.6), p < 0.001].Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Conclusion: Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 vaccines
Idiopathic Inflammatory Myopathies
autoimmune disease
registries
vaccine hesitancy
Megjelenés:
Rheumatology. - 62 : 10 (2023), p. 3291-3301. -
További szerzők:
Naveen, R.
Houshmand, Nazanin
Moghadam Kia, Siamak
Joshi, Mrudula
Saha, Sreoshy
Jagtap, Kshitij
Agarwal, Vishwesh
Nune, Arvind
Nikiphorou, Elena (reumatológus)
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Velikova, Tsvetelina
Milchert, Marcin
Parodis, Ioannis
Gracia-Ramos, Abraham Edgar
Cavagna, Lorenzo
Kuwana, Masataka
Knitza, Johannes
Makol, Ashima
Patel, Aarat
Pauling, John D.
Wincup, Chris
Barman, Bhupen
Zamora Tehozol, Erick Adrian
Rojas Serrano, Jorge
García-De La Torre, Ignacio
Colunga-Pedraza, Iris J.
Merayo-Chalico, Javier
Chibuzo, Okwara Celestine
Katchamart, Wanruchada
Akawatcharangura Goo, Phonpen
Shumnalieva, Russka
Chen, Yi-Ming
Hoff, Leonardo Santos
El Kibbi, Lina
Halabi, Hussein
Vaidya, Binit
Sazliyana Shaharir, Syahrul
Hasan, A. T. M. Tanveer
Dey, Dzifa
Gutiérrez, Carlos-Enrique Toro
Caballero-Uribe, Carlo Vinicio
Lilleker, James B.
Salim, Babur
Gheita, Tamer A.
Chatterjee, Tulika
Distler, Oliver
Saavedra, Miguel A.
Day, Jessica
Chinoy, Hector
Nagy-Vincze Melinda (1985-) (orvos)
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.